Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway | Zendy

Susan C. Schiavi | Zendy; Rosa Maria Affonso Moysés | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway

Author(s) -

Susan C. Schiavi,

Rosa Maria Affonso Moysés

Publication year - 2016

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1016/j.kint.2016.03.028

Subject(s) - renal osteodystrophy , osteoblast , endocrinology , medicine , catenin , wnt signaling pathway , microbiology and biotechnology , signal transduction , chemistry , biology , kidney disease , biochemistry , in vitro

Although recognized as a major complication of chronic kidney disease (CKD), the pathophysiology of the CKD-related mineral and bone disorder (CKD-MBD) is not completely understood. Recently, the inhibition of Wnt/β-catenin pathway in osteocytes by sclerostin has been shown to play a role in CKD-MBD. The study by Carrilo-Lopez et al. confirms this inhibition in an experimental model of CKD. Moreover, they describe direct actions of FGF23-Klotho on osteoblasts, increasing the expression of DKK1, another Wnt/β-catenin pathway inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research